GNRO — Geneuro SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement
Brief: Geneuro Launches Capital Increase With Indicative Amount Of EUR 5 Million
Brief: Geneuro: Independent Data Monitoring Committee Recommends Continuing Temelimab Trial In Long COVID
Brief: Geneuro and Alphabet's Verily Collaborate To Advance Long-Covid Research
Brief: Geneuro H1 Net Loss Widens To EUR 6.9 Mln
Brief: Geneuro Says Study Shows Link Between SARS‑COV‑2 Infection And HERV-W Activation In Hospitalized Psychotic Patients
Brief: Euronext Announces Results Of Annual Review For CAC Family Indices
Brief: Geneuro End-June Cash Position At 8 Million Euros
Brief: GeNeuro End-Q1 Cash Position Totals 9.5 Million Euros
Brief: Geneuro 2022 Operating Loss Widens To EUR 11.23 Mln
Brief: EIB, GeNeuro Sign EUR 25 Million Credit Line
Brief: GeNeuro Announces First Patients Recruitment In Trial Assessing Temelimab Against Long-Covid
Brief: Geneuro’S Protect-MS Phase 2 Trial Data Confirms Synergistic Neuroprotective Potential Of Temelimab In MS
Brief: Geneuro Reports EUR 10 Million In Cash At June 30, 2022
Brief: Geneuro: Publication Confirms Preclinical Therapeutic Effect Of Anti-HERV-K ENV Antibody
Brief: Geneuro Will Contribute Its Expertise In Human Endogenous Retroviruses To The €6.8M EU-Funded HERVCOV Precision Medicine Project